Table 4.
Pharmacokinetics parameters
| Parameters | NMP suspension | NMP-NLC |
|---|---|---|
|
| ||
| Cmax (µg/mL) | 11.887±2.464 | 32.516±7.151* |
| Tmax (h) | 3.000±0.540 | 0.250±0.500** |
| t1/2 (h) | 4.905±1.013 | 10.160±4.566 |
| AUC0–∞ (µg/mL*h) | 45.691±7.667 | 73.546±8.933* |
| AUMC0–∞ (µg/mL*h2) | 382.679±3.482 | 818.153±2.504*** |
| Cl/F (mg/kg)/(µg/mL)/h | 0.875±0.007 | 0.544±0.002*** |
| MRT (h) | 8.375±0.006 | 11.124±0.444** |
Notes: Rats were given a single oral administration at a dose of 40 mg/kg of NMP-NLC and NMP suspension. Results are represented as mean ± SD (n=7).
*
P<0.05,
**
P<0.01,
***
P<0.001, compared to the corresponding parameters of NMP suspension.
Abbreviations: AUC0–∞, the area under the concentration–time curve; AUMC, the area under moment curve; Cl/F, the clearance rate in plasma; Cmax, the maximum concentration; MRT, mean residence time; NMP-NLC, nimodipine-loaded nanostructured lipid carriers; Tmax, the time of maximum concentration; t1/2, the half-life of plasma.